Genome editing is transforming the way biological science is done and accelerating medical breakthroughs. CRISPR technology has reduced the barrier to creating predictable changes to DNA, encouraging scientific investigators and entrepreneurs to adopt and use the technology. However, robust and rigorous computational tools are critical for the correct analysis, interpretation and verification of biological results. We build precision algorithms for analyzing genome editing experimental data, and provide customized computational support to address critical questions in the processing of next-generation sequencing data. Please get in touch with us to get more information or to start a collaboration.
| Website | https://edilytics.com/ |
| Employees | 5 (3 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research |
| Keywords | Gene Editing Tools, Genome Editing, Therapeutics, Crispr Technology, Genetic Engineering, Biotechnology, Molecular Biology, Life Sciences, Biomedical Research, Drug Discovery, Gene Therapy, Genetic Modification, Scientific Research, Biotechnology Research, Pharmaceutical Research, Medical Breakthroughs, Precision Medicine, Genetic Sequencing |
| Competitors | Microsoft, SAP, IBM, Domo, Tableau, Qlik, TIBCO Streaming, BankOne, Sisense, Looker +43 more (view full list) |
Looking for a particular Edilytics employee's phone or email?
Cole Lyman is the CEO of Edilytics.
3 people are employed at Edilytics.
Edilytics is based in Cambridge, Massachusetts.